Respiratory syncytial virus vaccine effectiveness among US veterans, September, 2023 to March, 2024: a target trial emulation study
Top Cited Papers
- 20 January 2025
- journal article
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 25 (6) , 625-633
Abstract
No abstract availableKeywords
Funding Information
- Biomedical Advanced Research and Development Authority
- US Department of Veterans Affairs
- US Department of Health and Human Services
- US Food and Drug Administration
This publication has 25 references indexed in Scilit:
- Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysisThe Lancet, 2024
- RSV Vaccine Effectiveness Against Hospitalization Among US Adults 60 Years and OlderJAMA, 2024
- Late Mortality After COVID-19 Infection Among US Veterans vs Risk-Matched ComparatorsJAMA Internal Medicine, 2023
- Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older AdultsNew England Journal of Medicine, 2023
- Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older AdultsNew England Journal of Medicine, 2023
- Vaccine effectiveness of two-dose BNT162b2 against symptomatic and severe COVID-19 among adolescents in Brazil and Scotland over time: a test-negative case-control studyThe Lancet Infectious Diseases, 2022
- Comparison of Moderna versus Pfizer-BioNTech COVID-19 vaccine outcomes: A target trial emulation study in the U.S. Veterans Affairs healthcare systemeClinicalMedicine, 2022
- Mortality Associated With Influenza and Respiratory Syncytial Virus in the US, 1999-2018JAMA Network Open, 2022
- Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. VeteransNew England Journal of Medicine, 2021
- Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity‐score matched samplesStatistics in Medicine, 2009